Item 16. FORM 10-K SUMMARY

5K characters. Original on sec.gov · Markdown

Item 16. FORM 10-K SUMMARY

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, Abbott Laboratories has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


			ABBOTT LABORATORIES

			By			/s/ ROBERT B. FORD
						Robert B. Ford
						Chairman of the Board and Chief Executive Officer

			Date:			February 17, 2023

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of Abbott Laboratories on February 17, 2023 in the capacities indicated below.


/s/ ROBERT B. FORD						/s/ ROBERT E. FUNCK, JR.
Robert B. Ford						Robert E. Funck, Jr.
Chairman of the Board and Chief Executive Officer, and Director of Abbott Laboratories (principal executive officer)						Executive Vice President, Finance and Chief Financial Officer (principal financial officer)

/s/ PHILIP P. BOUDREAU
Philip P. Boudreau
Vice President, Finance and Controller (principal accounting officer)

/s/ ROBERT J. ALPERN						/s/ CLAIRE BABINEAUX-FONTENOT
Robert J. Alpern, M.D.						Claire Babineaux-Fontenot
Director of Abbott Laboratories						Director of Abbott Laboratories

/s/ SALLY E. BLOUNT						/s/ PAOLA GONZALEZ
Sally E. Blount, Ph.D.						Paola Gonzalez
Director of Abbott Laboratories						Director of Abbott Laboratories

/s/ MICHELLE A. KUMBIER						/s/ DARREN W. MCDEW
Michelle A. Kumbier						Darren W. McDew
Director of Abbott Laboratories						Director of Abbott Laboratories

/s/ NANCY MCKINSTRY						/s/ WILLIAM A. OSBORN
Nancy McKinstry						William A. Osborn
Director of Abbott Laboratories						Director of Abbott Laboratories

/s/ MICHAEL F. ROMAN						/s/ DANIEL J. STARKS
Michael F. Roman						Daniel J. Starks
Director of Abbott Laboratories						Director of Abbott Laboratories

/s/ JOHN G. STRATTON						/s/ GLENN F. TILTON
John G. Stratton						Glenn F. Tilton
Director of Abbott Laboratories						Director of Abbott Laboratories

ABBOTT LABORATORIES AND SUBSIDIARIES

SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS

FOR THE YEARS ENDED DECEMBER 31, 2022, 2021 AND 2020

(in millions)


Allowances for Doubtful Accounts and Product Returns	Balance at Beginning of Year		Provisions/ Charges to Income		Amounts Charged Off and Other Deductions		Balance at End of Year
2022	$	519	$	122	$	(141)	$	500
2021	460		145		(86)		519
2020	384		187		(111)		460

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors of Abbott Laboratories

Opinion on the Financial Statement Schedule

We have audited the consolidated financial statements of Abbott Laboratories and subsidiaries (the Company) as of December 31, 2022 and 2021, for each of the three years in the period ended December 31, 2022, and have issued our report thereon dated February 17, 2023 (included elsewhere in this Annual Report on Form 10-K). Our audits of the consolidated financial statements included the financial statement schedule listed in Item 15(a)(2) of this Annual Report on Form 10-K (the “schedule”). This schedule is the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s schedule, based on our audits.

In our opinion, the schedule presents fairly, in all material respects, the information set forth therein when considered in conjunction with the consolidated financial statements.

/s/ Ernst & Young LLP

Chicago, Illinois

February 17, 2023

Previous: Item 15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES